Avi Nandi

Avi Nandi's Title

Avi Nandi currently holds the esteemed position of Chief Technical Officer. In this role, he oversees technical strategies and innovations related to gene therapy, viral vectors, and vaccines. His leadership is crucial in driving the company's technical advancements and ensuring that the pipeline of products is developed efficiently and adheres to regulatory standards.

Avi Nandi's Education and Expertise

Avi Nandi's educational background is both extensive and specialized. He holds a Master's degree in Biology, which provided him with a strong foundation in the life sciences. To complement his technical expertise, he earned an MBA in October 2021, equipping him with critical business acumen. This combination of scientific and managerial education enables him to navigate the complex landscape of biotech innovation and commercialization adeptly.

Avi Nandi's Experience

Avi Nandi brings over 15 years of industry experience to his role as Chief Technical Officer. His career spans significant contributions to gene therapy, viral vectors, and vaccines. Notably, he played a pivotal role in the regulatory approval of ZOLGENSMA in the US and over 10 other markets. His experience includes supporting a pipeline of over 15 gene therapy products from preclinical to Phase III development, and leading the development of four gene therapy manufacturing processes across multiple GMP and laboratory sites. His previous roles include Global Head of Technical Development at AveXis / Novartis Gene Therapies and various technical and leadership positions at Seqirus / CSL, Novartis Vaccines and Diagnostics, and Harvard Medical School.

Avi Nandi's Achievements

One of Avi Nandi's most notable achievements is his contribution to the regulatory approval of ZOLGENSMA, a groundbreaking gene therapy for spinal muscular atrophy, in the US and over 10 other markets. This approval is a significant milestone in the field of gene therapy and showcases his expertise in navigating complex regulatory environments. Additionally, he has supported the development of over 15 gene therapy products from preclinical to Phase III, demonstrating his capability to manage products through various stages of development. His leadership in developing four gene therapy manufacturing processes across multiple sites underscores his technical prowess and strategic vision.

Avi Nandi's Background

Avi Nandi's background is rich with diverse experiences in the biotechnology sector. His early career included research as a Viral Pathogenesis Scientist at Harvard Medical School, where he honed his skills in virology and cell culture. He then transitioned to industry roles, working as a Technical Development Scientist at Novartis Vaccines and Diagnostics and later as Head of Virology and Cell Culture at Seqirus / CSL. His tenure at AveXis / Novartis Gene Therapies as Global Head of Technical Development saw him leading technical strategies and innovations in gene therapy. This varied background has equipped him with a deep understanding of both the scientific and operational aspects of biotechnology.